Source comparison
PT-141 & Melanotan-2: Mechanism Comparison
MC1R (Melanocytes) Low affinity. Minimal activation at therapeutic doses High affinity. Full agonist at nanomolar concentrations Melanotan-2 produces pigmentation; PT-141 does not MC3R (Hypothalamus, peripheral tissue) Moderate agonist activity Full agonist Me
This comparison does not assign a generated winner or score.
- MC1R (Melanocytes)
- Low affinity. Minimal activation at therapeutic doses
- High affinity. Full agonist at nanomolar concentrations
- Melanotan-2 produces pigmentation; PT-141 does not
- MC3R (Hypothalamus, peripheral tissue)
- Moderate agonist activity
- Full agonist
- Melanotan-2 produces greater sympathetic activation and energy expenditure
- MC4R (Hypothalamus, adipose, muscle)
- Selective high-affinity agonist
- Nonselective full agonist
- Both activate central arousal pathways; Melanotan-2 adds peripheral metabolic effects
- MC5R (Exocrine glands)
- Negligible activity
- Moderate agonist
- Melanotan-2 may influence sebaceous gland activity; PT-141 does not
- Clinical Side Effect Profile
- Nausea (40%), transient hypertension, flushing
- Nausea (30%), tanning, appetite suppression, tachycardia, flushing
- PT-141 side effects are primarily central; Melanotan-2 affects multiple systems
- Primary Research Application
- Isolated central melanocortin signaling studies, arousal pathway research
- Multi-system melanocortin research, pigmentation studies, metabolic modulation
- Selectivity vs breadth determines which peptide fits the protocol